InMed Pharmaceuticals Inc.(INM)Earnings, Financials & Key Ratios
INM•NASDAQ
$0.73
$2M mkt cap·Price updated May 6, 2026
AboutInMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Show more
- Revenue$5M+7.5%
- EBITDA-$7M+1.9%
- Net Income-$8M-6.3%
- EPS (Diluted)-11.44+58.5%
- Gross Margin34.53%+44.2%
- EBITDA Margin-149.38%+8.8%
- Operating Margin-160.2%+9.5%
- Net Margin-165.14%+1.1%
- ROE-72.1%
- ROIC-177.35%-4.2%
- Debt/Equity0.06-47.2%
- Interest Coverage-21.22
INM Key Insights
InMed Pharmaceuticals Inc. (INM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
INM Price & Volume
InMed Pharmaceuticals Inc. (INM) stock price & volume — 10-year historical chart
Loading chart...
INM Growth Metrics
InMed Pharmaceuticals Inc. (INM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years65.55%
TTM16960.11%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-14.57%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2141.65%
Return on Capital
10 Years-100.42%
5 Years-105.52%
3 Years-70.07%
Last Year-67.13%
INM Peer Comparison
InMed Pharmaceuticals Inc. (INM) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 YCBD | 9.19M | 0.91 | -0.84 | -1.5% | -6.51% | -3.64% | 107.70 | |
 ATAI | 1B | 4.17 | -4.48 | -1.91% | -51.09% | -96.43% | 0.21 | |
 MNMD | 2.04B | 20.69 | -10.04 | -55.3% | ||||
 SNDL | 373.25M | 1.44 | -32.61 | 2.82% | -1.17% | -1% | 0.15 | |
 CRBP | 137.7M | 10.99 | -1.86 | -65.76% | 0.01 | |||
 AXSM | 11.46B | 222.63 | -60.50 | 65.55% | -26.59% | -260.01% | 2.73 | |
 GEVO | 497.05M | 2.05 | -14.64 | 8.49% | 0.75% | 0.25% | 0.01 | |
 CDXS | 241.71M | 2.66 | -5.32 | 18.61% | -62.47% | -90.51% | 1.45 |
Compare INM vs Peers
InMed Pharmaceuticals Inc. (INM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INM Income Statement
InMed Pharmaceuticals Inc. (INM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 1.09M | 4.14M | 4.6M | 4.94M | 5.55M |
| Revenue Growth % | - | - | - | - | - | - | 279.61% | 11.18% | 7.5% | 16960.11% |
| Cost of Goods Sold | 0 | 92.78K | 93.94K | 183.09K | 0 | 545.89K | 2.73M | 3.5M | 3.24M | 638.79M |
| COGS % of Revenue | - | - | - | - | - | 50.11% | 66.07% | 76.06% | 65.47% | - |
| Gross Profit | 0▲ 0% | -92.78K▲ 0% | -93.94K▼ 1.3% | -183.09K▼ 94.9% | 0▲ 100.0% | 543.55K▲ 0% | 1.4M▲ 158.1% | 1.1M▼ 21.5% | 1.71M▲ 55.0% | 185.56M▲ 0% |
| Gross Margin % | - | - | - | - | - | 49.89% | 33.93% | 23.94% | 34.53% | 22.51% |
| Gross Profit Growth % | - | - | -1.25% | -94.9% | 100% | - | 158.13% | -21.53% | 55.02% | - |
| Operating Expenses | 3.44M | 6.69M | 10.39M | 8.97M | 12.17M | 14.34M | 9.78M | 9.24M | 9.62M | 2.26B |
| OpEx % of Revenue | - | - | - | - | - | 1315.85% | 236.53% | 200.87% | 194.73% | - |
| Selling, General & Admin | 2.79M | 5.17M | 6M | 3.16M | 5.55M | 6.87M | 5.85M | 5.8M | 6.56M | 1.63B |
| SG&A % of Revenue | - | - | - | - | - | 630.33% | 141.4% | 126.11% | 132.68% | - |
| Research & Development | 573.72K | 1.52M | 4.3M | 5.81M | 6.62M | 7.28M | 3.73M | 3.22M | 2.85M | 632.28M |
| R&D % of Revenue | - | - | - | - | - | 668.48% | 90.24% | 69.98% | 57.74% | - |
| Other Operating Expenses | 75.22K | 0 | 94.72K | 0 | 0 | 185.66K | 202.25K | 219.6K | 212.84K | 105.51K |
| Operating Income | -3.44M▲ 0% | -6.78M▼ 97.1% | -10.36M▼ 52.8% | -9.15M▲ 11.7% | -12.17M▼ 33.0% | -13.79M▼ 13.3% | -8.38M▲ 39.2% | -8.13M▲ 2.9% | -7.92M▲ 2.7% | -2.07B▲ 0% |
| Operating Margin % | - | - | - | - | - | -1265.95% | -202.6% | -176.92% | -160.2% | -251.58% |
| Operating Income Growth % | -87.19% | -97.07% | -52.83% | 11.66% | -33.01% | -13.32% | 39.25% | 2.92% | 2.66% | - |
| EBITDA | -3.36M | -6.69M | -10.26M | -8.97M | -12.02M | -13.28M | -7.78M | -7.53M | -7.38M | -2.07B |
| EBITDA Margin % | - | - | - | - | - | -1218.98% | -188.19% | -163.77% | -149.38% | -251.51% |
| EBITDA Growth % | -90.07% | -98.81% | -53.46% | 12.63% | -34.05% | -10.47% | 41.39% | 3.25% | 1.95% | -28739.19% |
| D&A (Non-Cash Add-back) | 75.22K | 89.6K | 94.72K | 183.09K | 149.84K | 511.79K | 596K | 604.52K | 534.73K | 574.94K |
| EBIT | -3.44M | -6.78M | -10.36M | -8.94M | -12.32M | -13.79M | -8.38M | -7.67M | -7.79M | -9.27M |
| Net Interest Income | 0 | 0 | 0 | 107.27K | -344.33K | 123.72K | 652.37K | 721.97K | -216.57K | 244.15K |
| Interest Income | 0 | 69.55K | 330.44K | 125.89K | 16.02K | 123.72K | 652.37K | 721.97K | 156.53K | 264.15K |
| Interest Expense | 495 | 0 | 0 | 18.62K | 360.35K | 0 | 0 | 0 | 373.11K | 20K |
| Other Income/Expense | -495 | 69.77K | 262.1K | 211.71K | -478.14K | -4.81M | 444.26K | 465.98K | -244.14K | 39.35M |
| Pretax Income | -3.44M▲ 0% | -6.71M▼ 95.0% | -10.1M▼ 50.5% | -8.94M▲ 11.5% | -12.65M▼ 41.5% | -18.6M▼ 47.0% | -7.93M▲ 57.3% | -7.67M▲ 3.4% | -8.16M▼ 6.4% | -2.03B▲ 0% |
| Pretax Margin % | - | - | - | - | - | -1707.32% | -191.86% | -166.79% | -165.14% | -36689.89% |
| Income Tax | 495 | 0 | -262.1K | 0 | 0 | 0 | 13.1K | 7.1K | 0 | 0 |
| Effective Tax Rate % | -0.01% | 0% | 2.6% | 0% | 0% | 0% | -0.17% | -0.09% | 0% | 0% |
| Net Income | -3.44M▲ 0% | -6.71M▼ 95.0% | -10.01M▼ 49.2% | -8.94M▲ 10.7% | -12.65M▼ 41.5% | -18.6M▼ 47.0% | -7.95M▲ 57.3% | -7.68M▲ 3.4% | -8.16M▼ 6.3% | -9.07M▲ 0% |
| Net Margin % | - | - | - | - | - | -1707.32% | -192.18% | -166.94% | -165.14% | -1.1% |
| Net Income Growth % | -87.22% | -95.01% | -49.22% | 10.7% | -41.5% | -47.04% | 57.27% | 3.42% | -6.34% | -14.57% |
| Net Income (Continuing) | -3.44M | -6.71M | -10.01M | -8.94M | -12.65M | -18.6M | -7.95M | -7.68M | -8.16M | -9.07M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -810.55▲ 0% | -1032.30▼ 27.4% | -1264.97▼ 22.5% | -1161.21▲ 8.2% | -938.91▲ 19.1% | -21350.51▼ 2174.0% | -86.00▲ 99.6% | -27.55▲ 68.0% | -11.44▲ 58.5% | -2293.04▲ 0% |
| EPS Growth % | -25.95% | -27.36% | -22.54% | 8.2% | 19.14% | -2173.97% | 99.6% | 67.97% | 58.48% | -2141.65% |
| EPS (Basic) | -810.55 | -1032.30 | -1264.97 | -1161.21 | -938.91 | -21350.51 | -86.00 | -27.55 | -11.44 | - |
| Diluted Shares Outstanding | 5.87K | 8.63K | 10.38K | 10.44K | 13.44K | 1.12K | 122.42K | 381.05K | 975.99K | 3.95K |
| Basic Shares Outstanding | 5.87K | 8.63K | 10.38K | 10.44K | 13.44K | 1.12K | 122.42K | 381.05K | 975.99K | 3.95K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
INM Balance Sheet
InMed Pharmaceuticals Inc. (INM) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 5.34M | 20.33M | 14.13M | 6.31M | 8.38M | 12.36M | 11.33M | 8.69M | 12.87M | 8.79B |
| Cash & Short-Term Investments | 5.16M | 20.13M | 13.74M | 5.85M | 7.41M | 8.01M | 8.91M | 6.57M | 11.08M | 7B |
| Cash Only | 5.16M | 18.35M | 9.81M | 5.81M | 7.36M | 7.95M | 8.91M | 6.57M | 11.08M | 6.95B |
| Short-Term Investments | 0 | 1.78M | 3.93M | 42.38K | 46.46K | 57.67K | 0 | 0 | 0 | 42.67M |
| Accounts Receivable | 45.48K | 40.58K | 64.74K | 45.34K | 11.92K | 113.31K | 260.4K | 352.84K | 465.1K | 251.05K |
| Days Sales Outstanding | - | - | - | - | - | 37.96 | 22.98 | 28.01 | 34.35 | 5.67K |
| Inventory | 0 | 0 | 0 | 0 | 0 | 3.21M | 1.62M | 1.24M | 961.17K | 947.9M |
| Days Inventory Outstanding | - | - | - | - | - | 2.14K | 215.91 | 129.88 | 108.41 | 262.91 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 2 | 542.46K | 520.81K | 365.13K | 843M |
| Total Non-Current Assets | 1.07M | 1.01M | 944.96K | 1.49M | 1.4M | 4.11M | 2.77M | 3.13M | 2.71M | 2.4B |
| Property, Plant & Equipment | 20.8K | 42.38K | 42.53K | 403.49K | 326.6K | 1.16M | 723.43K | 1.25M | 992.2K | 764.25M |
| Fixed Asset Turnover | - | - | - | - | - | 0.94x | 5.72x | 3.68x | 4.98x | 0.01x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.05M | 968.42K | 902.44K | 1.09M | 1.06M | 2.71M | 1.95M | 1.78M | 1.62M | 1.54B |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 14.65K | 227.38K | 104.91K | 100K | 100K | 200.2M |
| Total Assets | 6.41M▲ 0% | 21.34M▲ 232.9% | 15.07M▼ 29.4% | 7.8M▼ 48.2% | 9.78M▲ 25.4% | 16.46M▲ 68.3% | 14.11M▼ 14.3% | 11.82M▼ 16.2% | 15.58M▲ 31.8% | 11.19B▲ 0% |
| Asset Turnover | - | - | - | - | - | 0.07x | 0.29x | 0.39x | 0.32x | 0.00x |
| Asset Growth % | 402.07% | 232.9% | -29.36% | -48.24% | 25.36% | 68.29% | -14.31% | -16.19% | 31.78% | 259102.99% |
| Total Current Liabilities | 284.24K | 713.02K | 1.19M | 1.68M | 2.22M | 4.27M | 2M | 1.97M | 1.84M | 1.48B |
| Accounts Payable | 284.24K | 713.02K | 1.56M | 0 | 775.13K | 1.5M | 544.18K | 626.19K | 370.14K | 228.81K |
| Days Payables Outstanding | - | 2.81K | 6.07K | - | - | 1K | 72.69 | 65.36 | 41.75 | 0.24 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | -372.38K | 1.61M | 880.21K | 643.64K | 558.48K | 488.28K | 490.4K | 1.48B |
| Current Ratio | 18.79x | 28.51x | 11.87x | 3.77x | 3.78x | 2.89x | 5.66x | 4.41x | 6.99x | 6.99x |
| Quick Ratio | 18.79x | 28.51x | 11.87x | 3.77x | 3.78x | 2.14x | 4.86x | 3.78x | 6.47x | 6.47x |
| Cash Conversion Cycle | - | - | - | - | - | 1.18K | 166.2 | 92.53 | 101.01 | 5.93K |
| Total Non-Current Liabilities | 0 | 0 | 0 | 248.01K | 189.29K | 501.39K | 15.99K | 644.87K | 305.75K | 123.83M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 123.83M |
| Capital Lease Obligations | 0 | 0 | 0 | 248.01K | 189.29K | 501.39K | 15.99K | 644.87K | 305.75K | 1.2M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | -470.44K |
| Total Liabilities | 284.24K | 713.02K | 1.19M | 1.92M | 2.4M | 4.77M | 2.02M | 2.62M | 2.15M | 1.6B |
| Total Debt | 0 | 0 | 0 | 316.98K | 269.77K | 1.02M | 391.71K | 962.66K | 741.26K | 123.83M |
| Net Debt | -5.16M | -18.35M | -9.81M | -5.49M | -7.09M | -6.93M | -8.52M | -5.61M | -10.33M | -6.83B |
| Debt / Equity | - | - | - | 0.05x | 0.04x | 0.09x | 0.03x | 0.10x | 0.06x | 0.06x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.06x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 3.29x |
| Interest Coverage | -6945.97x | - | - | -491.56x | -33.78x | - | - | - | -21.22x | -463.35x |
| Total Equity | 6.13M▲ 0% | 20.62M▲ 236.7% | 13.88M▼ 32.7% | 5.88M▼ 57.7% | 7.38M▲ 25.5% | 11.69M▲ 58.4% | 12.09M▲ 3.4% | 9.21M▼ 23.9% | 13.43M▲ 45.9% | 9.59B▲ 0% |
| Equity Growth % | 646.56% | 236.7% | -32.69% | -57.66% | 25.49% | 58.43% | 3.45% | -23.85% | 45.93% | 292955.14% |
| Book Value per Share | 1044.22 | 2389.03 | 1336.99 | 563.00 | 548.89 | 10425.18 | 98.75 | 24.16 | 13.77 | 999999.00 |
| Total Shareholders' Equity | 6.13M | 20.62M | 13.88M | 5.88M | 7.38M | 11.69M | 12.09M | 9.21M | 13.43M | 9.59B |
| Common Stock | 33.18M | 51.75M | 52.24M | 53.07M | 60.59M | 91.03M | 77.62M | 82.78M | 91.22M | 126.3M |
| Retained Earnings | -32.9M | -39.02M | -49.19M | -64.65M | -74.85M | -120.3M | -101.4M | -109.08M | -117.24M | -166.02M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 128.57K | 165.5K | 128.57K | 128.57K | 128.57K | 176.41K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INM Cash Flow Statement
InMed Pharmaceuticals Inc. (INM) cash flow — operating, investing & free cash flow history
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.37M | -3.68M | -6.68M | -7.37M | -9.79M | -15.58M | -7.28M | -6.99M | -7.77M | -7.77M |
| Operating CF Margin % | - | - | - | - | - | -1430.44% | -176.11% | -151.94% | -157.14% | - |
| Operating CF Growth % | -512.69% | -55.5% | -81.59% | -10.41% | -32.76% | -59.17% | 53.26% | 4.08% | -11.18% | -159100.55% |
| Net Income | -3.44M | -6.71M | -10.1M | -8.94M | -10.2M | -18.6M | -7.95M | -7.68M | -8.16M | -9.07M |
| Depreciation & Amortization | 75.22K | -92.78K | 94.72K | 183.09K | 120.87K | 511.79K | 596K | 604.52K | 534.73K | 314.96M |
| Stock-Based Compensation | 1.17M | 2.43M | 3.11M | 0 | 610.19K | 697.89K | 278.15K | 137.71K | 119.31K | 45.54M |
| Deferred Taxes | 0 | -2.25M | 2 | 0 | -242.39K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 2.51M | -71.39K | 1.02M | 374.23K | 4.88M | 356.09K | 316.82K | 78.32K | -587.97M |
| Working Capital Changes | -165.8K | 431.4K | 283.89K | 358.11K | -450.45K | -3.07M | -565.82K | -369.34K | -337.17K | -795.44K |
| Change in Receivables | 0 | 4.55K | -24.08K | 17.27K | 40.2K | -40.01K | -219.15K | -92.44K | -114.69K | 134.32K |
| Change in Inventory | 0 | -431.94K | 0 | 0 | 0 | -2M | 565.56K | 66.22K | 283.15K | 38.64K |
| Change in Payables | 0 | 431.94K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -459.5K |
| Cash from Investing | -19.52K | -1.88M | -2.11M | 3.79M | -1.73K | -673K | -661.8K | -9.29K | 0 | 0 |
| Capital Expenditures | -19.52K | -43.8K | -27.04K | -42.57K | -1.73K | -39.11K | -161.8K | -9.29K | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | 3.59% | 3.91% | 0.2% | - | - |
| Acquisitions | 0 | 0 | 0 | 541 | 0 | -208.89K | -500K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -17.02K | 0 | 0 | -425K | 0 | 0 | 0 | 0 |
| Cash from Financing | 7.5M | 19.27M | 272.5K | -30.99K | 10.85M | 15.07M | 10.68M | 4.65M | 12.27M | 10.96M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | -290.83K | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 207.57K | -30.99K | 1000K | 1000K | 1000K | 1000K | 1000K | 1.81M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -764.62K | -1.02M | 64.93K | 0 | -1.62M | -1.78M | 646 | -561.98K | 4.14M | 4.44M |
| Net Change in Cash | 5.12M▲ 0% | 13.25M▲ 159.0% | -8.58M▼ 164.7% | -4.05M▲ 52.8% | 1.56M▲ 138.5% | -1.19M▼ 176.2% | 2.74M▲ 330.6% | -2.34M▼ 185.6% | 4.5M▲ 292.4% | 6.95B▲ 0% |
| Free Cash Flow | -2.38M▲ 0% | -3.72M▼ 56.1% | -6.71M▼ 80.2% | -7.42M▼ 10.6% | -9.79M▼ 32.0% | -15.62M▼ 59.5% | -7.45M▲ 52.3% | -7M▲ 6.0% | -7.77M▼ 11.0% | -3.99B▲ 0% |
| FCF Margin % | - | - | - | - | - | -1434.03% | -180.02% | -152.14% | -157.14% | -483.69% |
| FCF Growth % | -516.34% | -56.06% | -80.18% | -10.6% | -32.02% | -59.54% | 52.35% | 6.04% | -11.03% | -54577.16% |
| FCF per Share | -406.57 | -431.14 | -645.83 | -710.40 | -728.65 | -13936.54 | -60.81 | -18.36 | -7.96 | -7.96 |
| FCF Conversion (FCF/Net Income) | 0.69x | 0.55x | 0.67x | 0.82x | 0.77x | 0.84x | 0.92x | 0.91x | 0.95x | 439.77x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 13.1K | 7.1K | 0 | 0 |
INM Key Ratios
InMed Pharmaceuticals Inc. (INM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -99.05% | -50.16% | -58.02% | -90.47% | -190.86% | -195.14% | -66.85% | -72.08% | -72.1% | -0.09% |
| Return on Invested Capital (ROIC) | -295.43% | -313.6% | -244.66% | -307.33% | -2713.96% | -410.45% | -150.95% | -170.27% | -177.35% | -177.35% |
| Gross Margin | - | - | - | - | - | 49.89% | 33.93% | 23.94% | 34.53% | 22.51% |
| Net Margin | - | - | - | - | - | -1707.32% | -192.18% | -166.94% | -165.14% | -1.1% |
| Debt / Equity | - | - | - | 0.05x | 0.04x | 0.09x | 0.03x | 0.10x | 0.06x | 0.06x |
| Interest Coverage | -6945.97x | - | - | -491.56x | -33.78x | - | - | - | -21.22x | -463.35x |
| FCF Conversion | 0.69x | 0.55x | 0.67x | 0.82x | 0.77x | 0.84x | 0.92x | 0.91x | 0.95x | 439.77x |
| Revenue Growth | - | - | - | - | - | - | 279.61% | 11.18% | 7.5% | 16960.11% |
INM Frequently Asked Questions
InMed Pharmaceuticals Inc. (INM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
InMed Pharmaceuticals Inc. (INM) reported $5.5M in revenue for fiscal year 2025. This represents a 226974% increase from $0.0M in 2001.
InMed Pharmaceuticals Inc. (INM) grew revenue by 7.5% over the past year. This is steady growth.
InMed Pharmaceuticals Inc. (INM) reported a net loss of $9.1M for fiscal year 2025.
Dividend & Returns
InMed Pharmaceuticals Inc. (INM) has a return on equity (ROE) of -72.1%. Negative ROE indicates the company is unprofitable.
InMed Pharmaceuticals Inc. (INM) had negative free cash flow of $3.99B in fiscal year 2025, likely due to heavy capital investments.
Explore More INM
InMed Pharmaceuticals Inc. (INM) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates